Celldex Therapeutics Inc. (CLDX)
NASDAQ: CLDX
· Real-Time Price · USD
19.65
-0.53 (-2.63%)
At close: May 13, 2025, 3:59 PM
19.53
-0.61%
After-hours: May 13, 2025, 06:09 PM EDT
-2.63% (1D)
| Bid | 19.19 |
| Market Cap | 1.3B |
| Revenue (ttm) | 7.02M |
| Net Income (ttm) | -157.86M |
| EPS (ttm) | -2.45 |
| PE Ratio (ttm) | -8.02 |
| Forward PE | -5.13 |
| Analyst | Buy |
| Ask | 22.05 |
| Volume | 546,567 |
| Avg. Volume (20D) | 778,404 |
| Open | 20.31 |
| Previous Close | 20.18 |
| Day's Range | 19.47 - 20.48 |
| 52-Week Range | 14.40 - 47.00 |
| Beta | 1.39 |
About CLDX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CLDX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CLDX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Celldex Therapeutics has released their quartely earnings
on May 8, 2025:
7 months ago
-12.06%
Celldex Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
9 months ago
-8.45%
Celldex Therapeutics shares are trading lower. The company announced topline results from its Phase 2 clinical trial of barzolvolimab.
